MAGEA3 and melanoma: However, the two largest phase III clinical trials targeting MAGEA3 immunotherapeutic as an adjuvant therapy for stage III melanoma and nonsmall cell lung cancer failed (26, 27), which is stagnating the progress of immunotherapeutic, and research on MAGEA3 also have declined.